Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.
Journal: The Journal of allergy and clinical immunology
Published: October 17, 2025
Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria.
Journal: The World Allergy Organization journal
Published: May 30, 2022
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
Journal: The Journal of allergy and clinical immunology
Published: June 24, 2020
Ligelizumab for Chronic Spontaneous Urticaria.
Journal: The New England journal of medicine
Published: October 03, 2019
Showing 1-5 of 5
Last Updated: 09/26/2026